Retatrutide: Eli Lilly’s Triple-Target Breakthrough in Metabolic Disease Therapy
Revolutionizing Obesity and Diabetes Treatment with Unmatched Efficacy Core Innovations and Mechanism of Action Triple-Receptor Agonist DesignRetatrutide (LY3437943) is the world’s first GLP-1R/GIPR/GCGR triple agonist, engineered to simultaneously activate: Structural Engineering Unprecedented Clinical Efficacy Parameter Retatrutide (12mg) Tirzepatide (15mg) Semaglutide (2.4mg) Weight Loss (48 wks) 24.2% 20.9% 17% HbA1c Reduction 2.5–3.0% 2.07% 1.75% Liver Fat […]